Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Non-Current Debt: 2021-2024

Historic Non-Current Debt for ProQR Therapeutics N.V (PRQR) over the last 4 years, with Dec 2024 value amounting to $4,896.

  • ProQR Therapeutics N.V's Non-Current Debt rose 106350.03% to $198.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $198.7 billion, marking a year-over-year increase of 106350.03%. This contributed to the annual value of $201.2 million for FY2021, which is N/A change from last year.
  • Latest data reveals that ProQR Therapeutics N.V reported Non-Current Debt of $201.2 million as of FY2021.
  • ProQR Therapeutics N.V's Non-Current Debt's 5-year high stood at $201.2 million during FY2021, with a 5-year trough of $201.2 million in FY2021.
  • Its 3-year average for Non-Current Debt is $2,329, with a median of $4,643 in 2023.
  • In the last 5 years, ProQR Therapeutics N.V's Non-Current Debt crashed by 100.01% in 2022 and then skyrocketed by 282.02% in 2023.
  • ProQR Therapeutics N.V's Non-Current Debt (Yearly) stood at $46.5 million in 2021, then tumbled by 100.01% to -$2,551 in 2022, then spiked by 282.02% to $4,643 in 2023, then grew by 5.46% to $4,896 in 2024.